

Product Datasheet

MUC2 Antibody (996/1) - BSA Free NB120-11197

Unit Size: 0.1 mg

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Reviews: 1 Publications: 13

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NB120-11197

Updated 3/4/2026 v.20.1

**Earn rewards for product
reviews and publications.**

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NB120-11197




NB120-11197

MUC2 Antibody (996/1) - BSA Free


Product Information	
Unit Size	0.1 mg
Concentration	1.0 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Monoclonal
Clone	996/1
Preservative	0.02% Sodium Azide
Isotype	IgG1
Purity	Protein A or G purified
Buffer	PBS
Target Molecular Weight	540 kDa
Product Description	
Host	Mouse
Gene ID	4583
Gene Symbol	MUC2
Species	Human, Mouse
Reactivity Notes	Please note that this antibody is reactive to Mouse and derived from the same host, Mouse. Mouse-On-Mouse blocking reagent may be needed for IHC and ICC experiments to reduce high background signal. You can find these reagents under catalog numbers PK-2200-NB and MP-2400-NB. Please contact Technical Support if you have any questions. Mouse reactivity reported in scientific literature (PMID: 24045942).
Specificity/Sensitivity	MUC2 Antibody (996/1) recognizes the human MUC2 mucin, and shows no cross-reactivity with MUC1, MUC3 or MUC4 mucins. In tissue sections colon, liver and prostate stain strongly. It recognizes malignant colonic mucosa and normal mucosa.
Immunogen	This MUC2 Antibody (996/1) was developed against MUC2 tandem repeat peptide
Product Application Details	
Applications	Western Blot, Immunohistochemistry-Paraffin, Flow Cytometry, Flow (Intracellular), Immunohistochemistry, Immunohistochemistry-Frozen, ICC/IF (Negative)
Recommended Dilutions	Western Blot 1:100-1:2000, Flow Cytometry 1:10-1:1000, Immunohistochemistry 1:10-1:500, Immunohistochemistry-Paraffin 1:10-1:500, Immunohistochemistry-Frozen 1:10-1:500, Flow (Intracellular), ICC/IF (Negative)
Application Notes	Membrane permeabilization is required for Flow Cytometry.

Images


MUC2-Antibody-996-1-Immunohistochemistry-NB120-11197-
img0009.jpg




MUC2-Antibody-996-1-Immunohistochemistry-NB120-11197-
img0011.jpg




Flow Cytometry: MUC2 Antibody (996/1) [NB120-11197] - An intracellular stain was performed on HeLa cells with MUC2 Antibody [996/1] NB120-11197AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.




Flow Cytometry: MUC2 Antibody (996/1) [NB120-11197] - Analysis of Allophycocyanin conjugate of NB120-11197. An intracellular stain was performed on HeLa cells with MUC2 (996/1) antibody NB120-11197APC (blue) and a matched isotype control NBP2-27287APC (orange). Cells were fixed with 4% PFA and then permeabl




Flow Cytometry: MUC2 Antibody (996/1) [NB120-11197] - Analysis of Allophycocyanin conjugate of NB120-11197. An intracellular stain was performed on NTERA-2 cells with MUC2 (996/1) antibody NB120-11197APC (blue) and a matched isotype control NBP2-27287APC (orange). Cells were fixed with 4% PFA and then permea




Flow (Intracellular): MUC2 Antibody (996/1) [NB120-11197] - An intracellular stain was performed on HeLa cells with MUC2 Antibody (996/1) NB120-11197AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.




Immunohistochemistry-Paraffin: Mouse Monoclonal MUC2 Antibody (996/1) [NB120-11197] - Staining of mouse colon tissue using MUC2 Antibody. Colon, MUC2 -Green, DAPI-Blue. Antibody dilution - 1:100. Image from a verified customer review.




MDA5-mediated dsRNA sensing is required for intestinal Adar deficiency-induced bowel inflammation and organoid death. **a** Representative images of Adar (green) and J2 (red) staining in organoids isolated from the ileum of Villin-CreERT2 *Adarf1/fl* mice and treated with or without 4-OHT (200 nM) for 3 days. Scale bars: 100 μ m. **b** Representative images of J2 staining (green) on ileal sections of *Adarf1/fl* and *Adar Δ gut* mice (3 dpi). Scale bars: 100 μ m. **c** Survival curves of *Adarf1/fl*, *Adar Δ gut*, and *Adar Δ gutMda5 $^{-/-}$* mice after tamoxifen induction (n = 5 for *Adarf1/fl*, n = 8 for *Adar Δ gut*, n = 6 for *Adar Δ gutMda5 $^{-/-}$*). **d**, h *Adarf1/fl*, *Adar Δ gut* and *Adar Δ gutMda5 $^{-/-}$* mice after tamoxifen induction at 3-dpi. **d** Small intestine and colon length (n = 5 for *Adarf1/fl*, n = 7 for *Adar Δ gut*, n = 6 for *Adar Δ gutMda5 $^{-/-}$*). **e** H&E staining of intestinal sections. Scale bars: 100 μ m. Shown on the right are quantifications of histopathological scores, and lengths of ileal crypts and villi (n = 5). **f** Representative images of TUNEL staining (green) on the ileal sections. Scale bars: 100 μ m. **g** Immunofluorescence of E-cadherin (red) staining. Scale bars: 100 μ m. **h** Immunofluorescence of Lysozyme (green) and Muc2 (red) staining. Scale bars: 100 μ m. **i** Western blot analysis of ileal samples (n = 3). **j** Representative images of the growth process of organoids isolated from the ileum of *Adar Δ gut* and *Adar Δ gutMda5 $^{-/-}$* mice treated with or without 4-OHT. Scale bars: 100 μ m. Data are presented as the mean \pm SEM. The statistical significance was analyzed using Log-rank (Mantel-Cox) test (Fig. 5c). The remaining statistical differences were determined using one-way ANOVA with multiple comparisons. Source data are provided in the Source data file. Image collected and cropped by CiteAb from the following open publication (<https://www.nature.com/articles/s41467-025-63554-4>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




MS-induced intestinal epithelium injury was CRHR1 dependent. Photomicrographs of hematoxylin and eosin (H&E) stained (A–E) and immunofluorescence of Mucin 2 (Muc2; mucous-forming protein) (F–J) in proximal colon in all experimental groups. Histological scores (K) were highest in MS, demonstrated injury in MS compared to control. Treatment with Antalarmin and Astressin prevented this MS-induced colonic injury, but not by Astressin-2 β . Crypt length in μ m (L) (red lines in photomicrographs A–E) and the number of Muc2+ goblet cells per crypt (M) were reduced by MS compared to control, and restored to control levels following Antalarmin and Astressin treatment. Astressin-2 β did not prevent these MS-induced effects. Myeloperoxidase (MPO; μ mol/mg protein) expression was increased in MS group and was reduced to a level similar to control by treatment with Antalarmin but not by treatment with Astressin or Astressin-2 β (N). Western blot analysis of NF- κ B showed an increase in the phosphorylated expression of NF- κ B in MS, which was prevented by Antalarmin administration, but not by Astressin or Astressin-2 β (O,P). Trans-cellular flux of HRP (ng/ml.cm 2 .min; Q) measured by Ussing Chamber was increased in MS and MS + Astressin-2 β groups, compared to control, but not in MS + Antalarmin and MS + Astressin groups (P). Results are means, \pm SD. p < 0.05 was considered significant. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/28492284>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




MS-induced intestinal epithelium injury was CRHR1 dependent. Photomicrographs of hematoxylin and eosin (H&E) stained (A–E) and immunofluorescence of Mucin 2 (Muc2; mucous-forming protein) (F–J) in proximal colon in all experimental groups. Histological scores (K) were highest in MS, demonstrated injury in MS compared to control. Treatment with Antalarmin and Astressin prevented this MS-induced colonic injury, but not by Astressin-2 β . Crypt length in μm (L) (red lines in photomicrographs A–E) and the number of Muc2+ goblet cells per crypt (M) were reduced by MS compared to control, and restored to control levels following Antalarmin and Astressin treatment. Astressin-2 β did not prevent these MS-induced effects. Myeloperoxidase (MPO; $\mu\text{mol}/\text{mg}$ protein) expression was increased in MS group and was reduced to a level similar to control by treatment with Antalarmin but not by treatment with Astressin or Astressin-2 β (N). Western blot analysis of NF- κB showed an increase in the phosphorylated expression of NF- κB in MS, which was prevented by Antalarmin administration, but not by Astressin or Astressin-2 β (O,P). Trans-cellular flux of HRP (ng/ml.cm².min; Q) measured by Ussing Chamber was increased in MS and MS + Astressin-2 β groups, compared to control, but not in MS + Antalarmin and MS + Astressin groups (P). Results are means, \pm SD. $p < 0.05$ was considered significant. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/28492284>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




MS-induced intestinal epithelium injury was CRHR1 dependent. Photomicrographs of hematoxylin and eosin (H&E) stained (A–E) and immunofluorescence of Mucin 2 (Muc2; mucous-forming protein) (F–J) in proximal colon in all experimental groups. Histological scores (K) were highest in MS, demonstrated injury in MS compared to control. Treatment with Antalarmin and Astressin prevented this MS-induced colonic injury, but not by Astressin-2 β . Crypt length in μm (L) (red lines in photomicrographs A–E) and the number of Muc2+ goblet cells per crypt (M) were reduced by MS compared to control, and restored to control levels following Antalarmin and Astressin treatment. Astressin-2 β did not prevent these MS-induced effects. Myeloperoxidase (MPO; $\mu\text{mol}/\text{mg}$ protein) expression was increased in MS group and was reduced to a level similar to control by treatment with Antalarmin but not by treatment with Astressin or Astressin-2 β (N). Western blot analysis of NF- κB showed an increase in the phosphorylated expression of NF- κB in MS, which was prevented by Antalarmin administration, but not by Astressin or Astressin-2 β (O,P). Trans-cellular flux of HRP (ng/ml.cm².min; Q) measured by Ussing Chamber was increased in MS and MS + Astressin-2 β groups, compared to control, but not in MS + Antalarmin and MS + Astressin groups (P). Results are means, \pm SD. $p < 0.05$ was considered significant. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/28492284>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



MS-induced intestinal epithelium injury was CRHR1 dependent. Photomicrographs of hematoxylin and eosin (H&E) stained (A–E) and immunofluorescence of Mucin 2 (Muc2; mucous-forming protein) (F–J) in proximal colon in all experimental groups. Histological scores (K) were highest in MS, demonstrated injury in MS compared to control. Treatment with Antalarmin and Astressin prevented this MS-induced colonic injury, but not by Astressin-2 β . Crypt length in μm (L) (red lines in photomicrographs A–E) and the number of Muc2+ goblet cells per crypt (M) were reduced by MS compared to control, and restored to control levels following Antalarmin and Astressin treatment. Astressin-2 β did not prevent these MS-induced effects. Myeloperoxidase (MPO; $\mu\text{mol}/\text{mg}$ protein) expression was increased in MS group and was reduced to a level similar to control by treatment with Antalarmin but not by treatment with Astressin or Astressin-2 β (N). Western blot analysis of NF- κB showed an increase in the phosphorylated expression of NF- κB in MS, which was prevented by Antalarmin administration, but not by Astressin or Astressin-2 β (O,P). Trans-cellular flux of HRP (ng/ml.cm².min; Q) measured by Ussing Chamber was increased in MS and MS + Astressin-2 β groups, compared to control, but not in MS + Antalarmin and MS + Astressin groups (P). Results are means, \pm -SD. $p < 0.05$ was considered significant. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/28492284>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



MS-induced intestinal epithelium injury was CRHR1 dependent. Photomicrographs of hematoxylin and eosin (H&E) stained (A–E) and immunofluorescence of Mucin 2 (Muc2; mucous-forming protein) (F–J) in proximal colon in all experimental groups. Histological scores (K) were highest in MS, demonstrated injury in MS compared to control. Treatment with Antalarmin and Astressin prevented this MS-induced colonic injury, but not by Astressin-2 β . Crypt length in μm (L) (red lines in photomicrographs A–E) and the number of Muc2+ goblet cells per crypt (M) were reduced by MS compared to control, and restored to control levels following Antalarmin and Astressin treatment. Astressin-2 β did not prevent these MS-induced effects. Myeloperoxidase (MPO; $\mu\text{mol}/\text{mg}$ protein) expression was increased in MS group and was reduced to a level similar to control by treatment with Antalarmin but not by treatment with Astressin or Astressin-2 β (N). Western blot analysis of NF- κB showed an increase in the phosphorylated expression of NF- κB in MS, which was prevented by Antalarmin administration, but not by Astressin or Astressin-2 β (O,P). Trans-cellular flux of HRP (ng/ml.cm².min; Q) measured by Ussing Chamber was increased in MS and MS + Astressin-2 β groups, compared to control, but not in MS + Antalarmin and MS + Astressin groups (P). Results are means, \pm -SD. $p < 0.05$ was considered significant. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/28492284>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Ichimiya S, Ahn S, Dixon M et al. Dual Role of NRF2 in Pancreatic Precursor Lesions Cancer Research Communications 2025-06-01 [PMID: 40407127]

Xie Z, Li M, Qian M et al. Co-Cultures of Lactobacillus acidophilus and Bacillus subtilis Enhance Mucosal Barrier by Modulating Gut Microbiota-Derived Short-Chain Fatty Acids Nutrients 2022-10-25 [PMID: 36364738] (Immunohistochemistry-Frozen, Mouse)

Capdevila C, Miller J, Cheng L, Kornberg A et Al. Time-resolved fate mapping identifies the intestinal upper crypt zone as an origin of Lgr5+ crypt base columnar cells Cell 2024-06-07 [PMID: 38848677]

Wanner N, Barnhart J, Apostolakis N Et al. Using the Autofluorescence Finder on the Sony ID7000(TM) Spectral Cell Analyzer to Identify and Unmix Multiple Highly Autofluorescent Murine Lung Populations Front Bioeng Biotechnol 2022-04-04 [PMID: 35372303] (FLOW, Mouse)

Details:

Citation using the Alexa Fluor 532 version of this antibody.

Bao L, Cui X, Wang X et al. Carbon Nanotubes Promote the Development of Intestinal Organoids through Regulating Extracellular Matrix Viscoelasticity and Intracellular Energy Metabolism ACS Nano 2021-10-26 [PMID: 34622660]

Details:

Citation using the PE format of this antibody.

Talbot S, Doyle B, et al. Vagal sensory neurons drive mucous cell metaplasia. J Allergy Clin Immunol 2020-06-01 [PMID: 31954778] (FLOW, Mouse)

Xu P, Xi Y, Zhu J et al. Intestinal Sulfation Is Essential to Protect Against Colitis and Colonic Carcinogenesis Gastroenterology 2021-04-02 [PMID: 33819483] (IF/IHC, Mouse)

Yang KS, Ciprani D, O'Shea A et al. EXTRACELLULAR VESICLE ANALYSIS ALLOWS FOR IDENTIFICATION OF INVASIVE IPMN Gastroenterology 2020-12-07 [PMID: 33301777] (Human)

Wu H, Chen QY, Wang WZ et al. Compound sophorae decoction enhances intestinal barrier function of dextran sodium sulfate induced colitis via regulating notch signaling pathway in mice Biomed Pharmacother 2020-11-17 [PMID: 33217689] (WB, Mouse)

Li B, Lee C et al. Inhibition of corticotropin-releasing hormone receptor 1 and activation of receptor 2 protect against colonic injury and promote epithelium repair. Sci Rep 2017-11-05 [PMID: 31748698] (IF/IHC, Mouse)

Yu Y, Lu J, Oliphant K et al. Maternal administration of probiotics promotes gut development in mouse offsprings PLoS ONE 2020-08-07 [PMID: 32764797] (Mouse)

Li B, Lee C, Filler T, Hock A Inhibition of corticotropin-releasing hormone receptor 1 and activation of receptor 2 protect against colonic injury and promote epithelium repair Sci Rep. 2017-05-10 [PMID: 28492284] (IF/IHC, Mouse)

More publications at <http://www.novusbio.com/NB120-11197>





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NB120-11197

NB820-59205	Human Colon Whole Tissue Lysate (Adult Whole Normal)
HAF007	Goat anti-Mouse IgG Secondary Antibody [HRP]
NB7539	Goat anti-Mouse IgG (H+L) Secondary Antibody [HRP]
NBP1-97005-0.5mg	Mouse IgG1 Isotype Control (MG1)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB120-11197

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

